Background
Apamistamab is a monoclonal antibody developed for targeted radiotherapy in hematologic malignancies. It is commonly used in radioimmunotherapy as a carrier for radioactive isotopes, facilitating the targeted destruction of malignant cells while minimizing damage to healthy tissues. It has been studied primarily in the context of conditioning regimens for hematopoietic stem cell transplantation, particularly in treating relapsed or refractory leukemias and lymphomas.• Protein tyrosine phosphatase receptor type C (PTPRC or CD45)., PMID:34039664• Immune receptor inhibition through enforced phosphatase recruitment., PMID:33087934• Orientation-dependent CD45 inhibition with viral and engineered ligands., PMID:39454026• Innate immune remodeling by short-term intensive fasting., PMID:34705313• CD45-negative follicular lymphoma., PMID:32163561• Dynamics of Cell Generation and Turnover in the Human Heart., PMID:26073943• The Roseoloviruses Downregulate the Protein Tyrosine Phosphatase PTPRC (CD45)., PMID:33952641• CD45-PET is a robust, non-invasive tool for imaging inflammation., PMID:39843738• Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing., PMID:28262555• The Protein Tyrosine Phosphatase SHP-1 (PTPN6) but Not CD45 (PTPRC) Is Essential for the Ligand-Mediated Regulation of CD22 in BCR-Ligated B Cells., PMID:33990399